Bruker Corporation, a leading scientific instruments, and high-value analytical and diagnostic solutions provider, announced the acquisition of ZONTAL Inc., an innovative platform provider for the digital transformation of analytical laboratories and integrated biopharma technical data solutions. The acquisition will strengthen Bruker BioSpin’s Integrated Data Solutions (IDS) software division, which includes Mestrelab Research, Arxspan, and Optimal.
ZONTAL products are designed to streamline communication between IT systems and lab devices, preserve digital assets from any source on an enterprise scale, eliminate manual processes through regulatory automation, and enable AI/ML-supported advanced analytics. The company offers the only enterprise-class, GxP-compliant data platform that manages data for full product lifecycles.
By integrating ZONTAL with Mestrelab Research, Arxspan scientific software solutions, and Optimal process analytical technology software, Bruker IDS division will expand its unique vendor-agnostic software solutions portfolio. This will enable global life-science, biopharma, and specialty chemicals customers to accelerate research, product development, and process optimization.
The ZONTAL acquisition will enable integrated digital laboratory and process data management, combining vendor-agnostic data storage and analysis, as well as workflow tools. This will help scientists realize the full potential of their analytical laboratory and process digital assets. The integration of different life-science tools will deliver integrated data solutions to more analytical and data scientists, researchers, and fully integrated, automated laboratories and manufacturing plants.
The acquisition is expected to help the biopharma industry by making data FAIR (Findable, Accessible, Interoperable, and Reusable), eliminating the biggest barrier to digital transformation in scientific research-based industries. It will also enable bi-directional communication between most types of instruments in the laboratory and all downstream applications, increasing the use of artificial intelligence in laboratory workflow optimization.
The financial terms of the acquisition were not disclosed, and ZONTAL expects 2023 revenues of greater than $5 million. Wolfgang Colsman, CEO, and cofounder of ZONTAL, said that the acquisition of ZONTAL by Bruker will create a new level of end-to-end solutions that will be transformative for life-science and biopharma customers.
Bruker’s acquisition of ZONTAL Inc. is a significant development in the biopharma industry. It will enable vendor-agnostic digital laboratory and biopharmaceutical process transformation, increase the use of artificial intelligence in laboratory workflow optimization, and improve data management, making data FAIR. The acquisition will enable integrated digital laboratory and process data management, combining vendor-agnostic data storage and analysis, as well as workflow tools, to help scientists realize the full potential of their analytical laboratory and process digital assets.
Image provided by ZONTAL Inc.